Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP793574.RA3mqmXVFNjMjWADCRfNe_IYiOey2ADikmbeuUVKKXLyw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP793574.RA3mqmXVFNjMjWADCRfNe_IYiOey2ADikmbeuUVKKXLyw130_assertion type Assertion NP793574.RA3mqmXVFNjMjWADCRfNe_IYiOey2ADikmbeuUVKKXLyw130_head.
- NP793574.RA3mqmXVFNjMjWADCRfNe_IYiOey2ADikmbeuUVKKXLyw130_assertion description "[The median 6-mercaptopurine dose administered during the maintenance therapy was 31% lower among patients with heterozygous TPMT alleles versus the rest (32.1mg/m(2)/day and 46.2mg/m(2)/day, p=0.005), though the myelosuppression and toxicities were similar in both the groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP793574.RA3mqmXVFNjMjWADCRfNe_IYiOey2ADikmbeuUVKKXLyw130_provenance.
- NP793574.RA3mqmXVFNjMjWADCRfNe_IYiOey2ADikmbeuUVKKXLyw130_assertion evidence source_evidence_literature NP793574.RA3mqmXVFNjMjWADCRfNe_IYiOey2ADikmbeuUVKKXLyw130_provenance.
- NP793574.RA3mqmXVFNjMjWADCRfNe_IYiOey2ADikmbeuUVKKXLyw130_assertion SIO_000772 20153897 NP793574.RA3mqmXVFNjMjWADCRfNe_IYiOey2ADikmbeuUVKKXLyw130_provenance.
- NP793574.RA3mqmXVFNjMjWADCRfNe_IYiOey2ADikmbeuUVKKXLyw130_assertion wasDerivedFrom befree-2016 NP793574.RA3mqmXVFNjMjWADCRfNe_IYiOey2ADikmbeuUVKKXLyw130_provenance.
- NP793574.RA3mqmXVFNjMjWADCRfNe_IYiOey2ADikmbeuUVKKXLyw130_assertion wasGeneratedBy ECO_0000203 NP793574.RA3mqmXVFNjMjWADCRfNe_IYiOey2ADikmbeuUVKKXLyw130_provenance.